Zevra Therapeutics, Inc.
ZVRA
$9.98
-$0.21-2.01%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 34.13M | 26.06M | 25.88M | 20.40M | 12.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 34.13M | 26.06M | 25.88M | 20.40M | 12.04M |
| Cost of Revenue | 1.52M | 1.24M | 12.38M | 1.35M | 1.37M |
| Gross Profit | 32.61M | 24.83M | 13.50M | 19.06M | 10.68M |
| SG&A Expenses | 20.45M | 16.94M | 20.78M | 19.55M | 16.18M |
| Depreciation & Amortization | 316.00K | 315.00K | 1.62M | 1.62M | 1.62M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.81M | 21.92M | 38.21M | 25.76M | 27.46M |
| Operating Income | 9.32M | 4.14M | -12.33M | -5.36M | -15.42M |
| Income Before Tax | 12.67M | -977.00K | 76.91M | -1.92M | -20.37M |
| Income Tax Expenses | 501.00K | -433.00K | 2.20M | 1.18M | 15.37M |
| Earnings from Continuing Operations | 12.17M | -544.00K | 74.71M | -3.10M | -35.74M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 12.17M | -544.00K | 74.71M | -3.10M | -35.74M |
| EBIT | 9.32M | 4.14M | -12.33M | -5.36M | -15.42M |
| EBITDA | 9.68M | 4.54M | -10.68M | -3.71M | -13.77M |
| EPS Basic | 0.21 | -0.01 | 1.27 | -0.06 | -0.67 |
| Normalized Basic EPS | 0.14 | -0.01 | -0.15 | -0.02 | -0.24 |
| EPS Diluted | 0.19 | -0.01 | 1.23 | -0.06 | -0.67 |
| Normalized Diluted EPS | 0.13 | -0.01 | -0.14 | -0.02 | -0.24 |
| Average Basic Shares Outstanding | 56.40M | 55.95M | 54.78M | 54.10M | 53.47M |
| Average Diluted Shares Outstanding | 58.70M | 55.95M | 56.32M | 54.10M | 53.47M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |